creasing age of the population and the improved survival of cardiovascular patients [3] . Stroke is the main complication of AF [4] : over 20% of ischemic strokes are linked to some form of arrhythmia [1] , and in these patients, they tend to be more severe than in non-arrhythmic patients [5] . About 40% of stroke survivors presents moderate to severe disability; applying these rates to the prevalent population, it has been calculated that
INTRODUCTION
Atrial fibrillation (AF) is the most prevalent form of arrhythmia, involving about 1-2% of the population in industrialized countries [1] . Its prevalence increases with age, reaching values above 5% in the over 65 years old, and of 9% in octogenarians [2] . In Italy, a prevalence of 1,000,000 AF patients was estimated for year 2010, and a further increase is expected due to the in- 
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around 384,000 are not autonomous in Italy due to stroke, and this figure is expected to rise up to 440,000 by 2020 [6] . Therapeutic goals in the management of AF patients include symptom control, but also the prevention of thromboembolic complications, stroke in primis. This was traditionally pursued with the administration of vitamin K antagonists (VKAs), or with antiplatelet agents, mainly aspirin, in subjects intolerant or contraindicated to VKAs [7] . In the last years, however, the class of novel oral anticoagulant agents (NOACs) has been introduced, which is associated with a more favorable risk/benefit ratio than VKAs. Until recently, dabigatran, a direct thrombin inhibitor, and rivaroxaban, a direct and selective coagulation factor Xa inhibitor, were the only NOACs licensed for thromboembolic prevention in non-valvular AF (NVAF, about 70% of all AF cases). Apixaban, also a direct and selective coagulation factor Xa inhibitor [8] , is facing the launch on the market for this indication, with the following reimbursement restrictions: NVAF with both CHA 2 DS 2 -VASc ≥ 1 1 and HAS-BLED > 3 2 , or TTR < 70% or objective difficulties in measuring INR [9] . Aim of the present analysis is the comparative economic evaluation of the use of the three available NOACs in the prevention of thromboembolic events in the Italian population of patients with NVAF with official indication for their use, according to current regulations.
METHODS
The analysis is conducted with a simulation study, performed through the adaptation and run of a previously published international model [10, 11] executed with epidemiological, clinical practice and unit costs pertinent to the Italian setting. The model is designed to reproduce the experience of a cohort of NVAF patients of user defined features, alternatively treated with the available therapeutic options: for the present study, dabigatran at two dose levels (110 mg/bid for the over 80 years old, 150 mg/bid for younger NVAF patients), rivaroxaban (20 mg/uid), and apixaban (5 mg/bid). During the lifetime simulation, events and consumed resources from the Italian National Health System perspective are recorded by the model; main clinical outcomes monitored are ischemic and hemorrhagic stroke, systemic thromboembolism, bleeds (both major and clinically relevant minor), cardiovascular hospitalizations, and death. Summary effectiveness indicators are overall survival, expressed in life years (LYs), and expected quality-adjusted survival, expressed in quality-adjusted life years (QALYs).
Model structure
The model is designed as a decision tree with Markov chains as branches; the experience of a NVAF patient is discretized in 17 possible and mutually exclusive health states (Figure 1) . Transitions among health states are determined by probability matrices derived from the relevant literature as detailed elsewhere [11] . At the end of each 6 week cycle, patients can stay in the current health state, or experience a clinical event and transition to the corresponding state; some events only imply a resource consumption and a temporary change in the utility (quality of life index), whilst others -i.e. stroke, myocardial infarction (MI), and systemic embolism -also modify the chance of incurring in further events. Stroke survivors distribute among subsequent health states basing on the assigned severity distribution of the specific event. Following a major bleeding, patients may continue to receive the initial anticoagulant, or switch to a second line treatment, associated with specific clinical event risks.
Population
The simulation is run on two cohorts (Table I) : the first (base-case) reproducing clinical and demographic features of the ARISTOTLE trial population [12] , the second those of a non-experimental population of NVAF patients studied by Olesen et al. [13] . In this cohort study, Olesen et al. assessed the individual risk factors composing the CHADS 2 and CHA 2 DS 2 -VASc score calculating the capability of the schemes to predict thromboembolism in a nationwide cohort of Danish real world patients.
Clinical outcomes rates
In general, the model assigns baseline clinical risks basing on the demographic and clinical features of the patients; these risks evolve ac-cording to the time elapsed from the beginning of the simulation, to the risk-modifying clinical events experienced by the patient, and to the preventive regimen administered. The effectiveness and safety profile of apixaban reflects event rates recorded in the ARISTOTLE trial [12] integrated with patient-level data made available by Dorian et al. [10] , which showed that apixaban was associated with a reduction in the risk of stroke or systemic embolism, in bleeding, and in all-cause mortality in AF patients, as compared to warfarin. The choice of the ARISTOTLE trial, a randomised head-to-head clinical trial, is related to the comparator, warfarin, which is common to the pivotal trials in AF of the other NOACs. The baseline risk profile can be adjusted for different distributions in the simulated population vs. the ARISTOTLE population of the CHADS 2 and the time in therapeutic range (TTR), for stroke and bleeding, respectively. Dabigatran was compared to warfarin in AF patients in the RELY trial, in which it demonstrated similar efficacy in stroke and thromboembolic prevention and lower bleeding risk, at the 110 mg bid, and superior stroke Alternative caseReal-world population [ [17] , and 1.3 [20] , respectively, are applied° For the duration of the trial follow-up ulation are specific for gender (10.8% in men and 15.6 for women), differently than for SE (9.4%) [21] .
During the simulation, patients may discontinue treatment, either completely, or by switching to another AC regimen, as a consequence of clinical events incurred, or for other reasons as described in Lip et al. [11] .
Besides the already described case fatality rates for stroke, bleeding, and MI, the population is subjected to a background mortality derived from ARISTOTLE for the duration of the trial follow-up; given the lack of sound comparative mortality rates, the same background mortality has been applied to all NOACs.
Beyond the trial duration, mortality is projected based on Gompertz distributions fitted on Italian age-and gender specific population rates [22] , corrected for the HRs associated to AF, MI, stroke, and SE, as shown in Table III .
Utility
Baseline utility assigned to the simulated population derives from a preference study 
Drug utilization
Aspirin -0.0020 [29] Warfarin -0.0120 [29] and embolism prevention, with similar bleeding risk, at the 150 mg/bid dose [14] .
Rivaroxaban was compared to warfarin in the ROCKET-AF trial, demonstrating non inferiority in the prevention of stroke and thromboembolism in NVAF patients, and similar bleeding risk [15] . Data from the VKA-suitable population of these trials (ARISTOTLE, RELY, and ROCK-ET-AF) were included in indirect treatment comparisons [11] , using warfarin as common comparator, to obtain relative risks or hazard ratios of each of the NOACs vs. apixaban, for each evaluated outcome (Table II) .
For apixaban, the risk of incurring an ischemic stroke (IS) is directly extrapolated from ARISTOTLE in the base case analysis, and adjusted for the CHADS 2 distribution in Olesen et al. for the alternative scenario; for the competing NOACs, the rate is calculated by applying the relevant HR to the apixaban hazard in both analyses. Increasing age is associated with higher IS risk; in the model, this is accounted for by applying a HR of 1.4 per decade [16] . Severity distribution of IS is classified according to the modified Rankin scale (mRS -mild 0-2; moderate 3-4; severe 5 and fatal 6) specific to the AC treatment and was derived from published literature (Table II) .
As with IS, in the base-case analysis the absolute intracranial hemorrhage (ICH) hazard rate for apixaban is directly obtained from ARISTOTLE; specific HRs are applied to these rates to determine the hazard rates for dabigatran and rivaroxaban. The model accounts for age-related increase in ICH risk by applying a 1.97 HR per decade [17] . Hemorrhagic strokes (HS) are determined as a treatment-specific percentage of ICHs; similarly, their severity distribution, again expressed in terms of mRS, is treatment-specific. IS and HS survivors are at risk of recurrence: this is modeled according to a real-life registry indicating a cumulative incidence of 4.1 and 3.0 per 100 patient-years, respectively [18] ; the severity distribution of recurrent strokes for all alternatives is conditional on the severity of the first stroke, as observed in ARISTOTLE and AVERROES [19] .
As with IS and ICH, the model accounts for increasing MI risk with advancing age of the cohort by applying an HR of 1.30 per decade [20] . MI case fatality rates applied in the sim- Table IV .
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Drug Daily dose (mg/die) Daily cost (€)
Costs
The analyses are performed taking the perspective of the National Health System (SSN); accordingly, only direct health care costs are considered: -Drug acquisition costs, at negotiated net prices [30] (Table V) ; -Routine visits [31] for all treated patients; -Acute event management (strokes, bleeds, myocardial infarction, and other CV hospitalizations); -Long-term post-event management for stroke, MI, and SE;
conducted on AF patients [28] . The model accounts for reduced preference for ASA administration, as reported in Gage et al. 1996 [29] ; temporary disutilities are assigned of the difference in costs over the difference in life years and quality-adjusted life years, respectively. The effect of parameter uncertainty on the results is assessed by probabilistic sensitivity analyses (PSA), in which the model is re-evaluated with 2000 sets of parameter values sampled from appropriate distributions.
The influence of single parameters on the results is evaluated with a series of one-way deterministic sensitivity analyses (DSA), in which the model is re-calculated using extreme parameter values, corresponding to the lower and upper limits of the 95% confidence interval; when this was unavailable from the original data, it has been calculated assuming a SEM equaling 25% of the mean.
Costs and benefits accruing after the first year are discounted at a 3.5% annual rate.
RESULTS
In Table VII , main results of the simulation for all alternatives at 1,2, and 3 years. Looking at the evolution of total costs associated to the use of the available NOACs, it can be seen that apixaban results less expensive than the comparators in the first years. Nevertheless, from Table VIII where lifetime ICER results are presented, it can be seen that total lifetime costs associated with apixaban treatment are expected to exceed those of the comparators. This can be easily explained with a well-known paradox in health economic analyses: life-extending therapies increase cost, simply because they prolong the survival of patients that continue to consume healthcare resources for a longer period of time. -Other health care costs associated with AC management (Table VI) . Stroke management costs have been elaborated based on data reported in an observational study conducted on 411 Italian stroke survivors, followed up for 12 months [32] : for each severity category within ischemic and hemorrhagic strokes, the mean long-term maintenance cost has been approximated to the monthly cost recorded in the second semester; the costs for the acute phase correspond to the sum of the corresponding DRG tariff [33] and the difference between the costs accrued in the first and second follow-up semester. For acute and long-term MI management, cost data are elaborated basing on three-year follow-up data reported for Italian MI survivors [34] . The costs attributed to the other clinical events considered are equaled to the corresponding DRG-based tariff [33] paid to the hospitals by the SSN. Other AC related costs considered are related to dyspepsia management (€ 71.46/year [35] , rates of dyspepsia from ARISTOTLE for apixaban and warfarin, from adjusted indirect comparison for dabigatran, and assumed equal to apixaban for rivaroxaban) and to renal function monitoring for dabigatran treated patients at risk (19.4%, according to RELY data), equaled to the corresponding tariff of € 8.16 [33] . All historical cost data have been actualized to 2013 values using official indices [22] .
Incremental cost/effectiveness
Lifetime results from the simulation are presented as incremental cost/effectiveness and incremental cost/utility ratios, i.e. as the ratio Figure 2 , Figure 3 , and Figure 4 , showing the impact of single parameters on the estimated ICERs in order of decreasing magnitude of effect. The most influential parameters are the daily costs of the compared molecules, but the corresponding ICERs remain well below commonly accepted WTP values. Probabilistic sensitivity analysis also substantially confirms the findings of the main analysis, as shown in Figure 5 , representing the distribution of the 2000 ICER estimates of the PSA. PSA results are also displayed as cost/effectiveness acceptability curves (Figure 6 ), in which the estimated probability of being the most cost/effective treatment is shown for every regimen at increasing willingness to pay (WTP) thresholds: apixaban is expected to be the best choice for any WTP above about 5,000 €/QALY gained. Apixaban has 99% and 100% expected probabilities of being effectiveness profile of the NOACs emerging from the adjusted indirect comparison. Dabigatran, at the 110 mg BID dose, appears associated with a lower ICH risk than apixaban, but this should be traded off with an apparent inferior protection against ischemic strokes; the latter can be mitigated with the higher dabigatran dose (150 mg BID) or with the use of rivaroxaban, but at the expense of much higher bleeding risks. However, from an economical point of view, neither trade-off is expected to be efficient.
In conclusion, analyses using the demonstrated relative effectiveness and safety profiles indicate that the different balance between ischemic protection and increased bleeding risk is more favourable from a health economics perspective with apixaban than with the other NOACs: the pharmacoeconomic analyses performed and the findings presented in this paper clearly support the economic value of apixaban in Italian NVAF patients.
Since cost effectiveness results appeared to be even more prominent when the model was simulated using real world data, it appears that our base-case may be conservative.
cost-effective in the head-to-head comparison with dabigatran 110 mg, for the conventional WTP thresholds of 20,000 and 30,000 €/QALY gained, respectively. Corresponding percentages for the comparison with dabigatran 150 mg and rivaroxaban are 92% and 94%, and 93% and 94%, for the same conventional WTP thresholds, respectively. Main results of the simulation run on a non-experimental population of NVAF patients [13] for all alternatives at 1,2, and 3 years, as well as in a lifetime horizon, are presented in Table IX .
Alternative scenario results (Table X) are even more favorable for apixaban: when compared with dabigatran (both 110 mg and 150 mg), the estimated ICERs are around 3,000 €/QALY gained ; in the comparison with rivaroxaban, apixaban is expected to dominate, being associated to lower costs and better effectiveness.
